Related Experiment Video

Updated: Jun 18, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K

Spleen tyrosine kinase (SYK): an emerging target for the assemblage of small molecule antitumor agents

Charanjit Kaur1, Amandeep Thakur2, Ke-Chi Liou2

  • 1School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India.

Expert Opinion on Investigational Drugs
|August 3, 2024
PubMed
Abstract

Insights

Spleen tyrosine kinase (SYK) is crucial in cancer cell survival and division, particularly in B-cell malignancies. Inhibiting SYK can induce cancer cell death, but challenges remain in clinical translation and toxicity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Spleen tyrosine kinase (SYK) is a nonreceptor tyrosine kinase implicated in cancer cell survival and proliferation.
  • Constitutive SYK activation is observed in various B-cell malignancies, where its inhibition triggers apoptosis.
  • SYK also functions as a tumor suppressor in certain contexts.

Purpose of the Study:

  • To review the role of SYK in the progression of specific cancers, including chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphomas (DLBCLs), acute myeloid leukemia (AML), and multiple myeloma (MM).
  • To discuss current and emerging therapeutic strategies targeting SYK in cancer treatment.
  • To highlight challenges in SYK inhibitor development and advocate for new structural templates.

Main Methods:

  • Literature review of SYK's role in cancer.
  • Analysis of therapeutic strategies involving SYK inhibitors.
  • Discussion of preclinical to clinical translation challenges and toxicity profiles.

Main Results:

  • SYK plays a significant role in the pathogenesis of several hematological malignancies.
  • Various therapeutic strategies targeting SYK are under investigation, including novel inhibitors and combination therapies.
  • Poor translation rates from preclinical to clinical studies and dose-limiting toxicities are major hurdles in SYK inhibitor development.

Conclusions:

  • Developing novel SYK inhibitory structural templates is critical for advancing cancer therapy.
  • Interdisciplinary efforts are needed to expand the arsenal of effective SYK inhibitors.
  • Addressing challenges in clinical translation and toxicity is paramount for successful SYK-targeted treatments.
Keywords:
BCR signalingSYKSpleen tyrosine kinaseleukemialymphomanon-Hodgkinprotein kinasetumor

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

7.9K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.5K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
77.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K